Selected Open Clinical Trials

For inquiries, visit or call 888-369-2427.

Gastrointestinal Cancer (Hepatic)

54F28-004: A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Cancer
Crystal Denlinger, MD

Gastrointestinal Cancer (Pancreatic)

54F28-002: A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer
Efrat Dotan, MD

ERP-RT-054: A Phase I Study of Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients with Pancreatic Cancer not Immediately Amenable to Surgical Resection (NCT01739439)
Joshua Meyer, MD

EMR200592-006: A Phase I Dose Escalation Study of TH-302 in Combination with Gemcitabine and Nab-Paclitaxel in Previously Untreated Patients with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Anthony Olszanski, MD

Genitourinary Cancer (Renal)

A Phase 1b, Open Label, Dose Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination with MK-3475 in Patients with Advanced Renal Cell Cancer
Elizabeth R. Plimack, MD

Genitourinary Cancer (Urothelial)

A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment with a Platinum Agent
Elizabeth R. Plimack, MD

Gynecologic Cancer (Ovarian)

IMGN0401: A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and Other FOLRI-Positive Solid Tumors
Hossein Borghaei, MD

54F28-003: A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
Gina Mantia-Smaldone, MD

GYN-064: A Phase I/II Trial of Weekly Paclitaxel in Combination with Ganetespib in Patients with Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer 9 (IND 120407) (NCT01962948)
Lainie Martin, MD

Head and Neck Cancer

A Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Ranee Mehra, MD

A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer
Ranee Mehra, MD

Hematologic Cancer (Leukemia)

Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory and Elderly AML and MDS
Patricia Kropf, MD


C28001: An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients with Metastatic Melanoma
Anthony Olszanski, MD


A Phase I, Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Colorectal Bioactivity in Healthy Volunteers
David Weinberg, MD


A Phase I Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Margaret von Mehren, MD

OER-SAR-043: A Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (IND 112423) (NCT01462630)
Margaret von Mehren, MD


A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Major Cancer Surgery
Nestor Esnaola, MD

Targeted Therapy

265-101: An Open-Label Dose-Escalation
Trial to Evaluate the Safety, Pharmacokinetics,
and Pharmacodynamics of Daily Oral MGCD265 Administered without Interruption to Subjects with Advanced Malignancies
Anthony Olszanski, MD

I30-MC-JSBA: A Phase 1 Study of LY2801653 in Patients with Advanced Cancer
Elizabeth R. Plimack, MD

Thoracic Cancer (Non-Small Cell Lung)

FER-TH-036: A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, in Combination with Erlotinib in Patients with Recurrent or Metastatic Non-Small Cell Lung Cancer (IND 111879) (NCT01471964)
Hossein Borghaei, MD